The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00273000|
Recruitment Status : Unknown
Verified October 2005 by Glostrup University Hospital, Copenhagen.
Recruitment status was: Recruiting
First Posted : January 9, 2006
Last Update Posted : September 11, 2006
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: GLP-2||Not Applicable|
The investigation will include 10 testpersons.
It will be a 2 fase study over 2 days.
day 1: The testperson will meet fasting, and take in a standard liquid meal, after this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.
day 2:The testperson will meet fasting, there wil be administered intraveneous GLP-2 in 3 increasing doses over 3 x 45 min.and one subcutaneous dose. During this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans|
|Study Start Date :||January 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273000
|Contact: Lasse Bremholm Hansen, MDemail@example.com|
|Copenhagen, Copenhagen City, Denmark, 2100|
|Contact: Lasse Bremholm Hansen, MD 004560927874 firstname.lastname@example.org|
|Sub-Investigator: Mads Hornum, MD|
|Principal Investigator:||Mads Hornum, MD||Glostrup University Hospital, Copenhagen|